Continuing EGFR TKI Therapy Beyond Progression in EGFR Mutation-Positive Lung Cancer: IMPRESS Provides New Guidance

Article

One of the major questions in the field of EGFR mutation-positive advanced NSCLC is whether we should continue patients on EGFR tyrosine kinase inhibitor (TKI) therapy as we transition to new treatment options because of acquired resistance after an initial good response.

Gilotrif (Afatinib) Reports Survival Benefit for EGFR Mutation-Positive Advanced NSCLC: Is it a Superior EGFR Inhibitor?

Article

One of the high profile presentations in the lung cancer track at ASCO 2014 was from Dr. James Yang of a pooled analysis of the LUX-Lung 3 and LUX-Lung 6 trials, each comparing Gilotrif (afatinib) to standard chemotherapy as first line treatment of EGFR mutation-positive advanced NSCLC, which for the first time demonstrated an actual survival benefit not seen in similarly designed trials with Iressa (gefitinib) or Tarceva (erlotinib).

Targeted Therapy as Adjuvant Treatment: Should We Extrapolate from Advanced NSCLC to Earlier Stage?

Article

This past week, I saw a new patient who had just moved from another part of the country and needed long-term management of her high risk lung cancer.  A never-smoking Asian woman, she was found to have a stage IIIA lung cancer with "N2" mediastinal lymph nodes involving cancer in her mid-chest.